While surgical resection of the underlying tumor is usually the first-line treatment for patients with endogenous CS [22], [23], after failed surgery, tumor recurrence, or in patients not eligible for surgery, pharmacological reduction of cortisol activity can also be achieved with GR antagonists. Here, NR3C1 is linked to neoplasm.